RSS-Feed abonnieren
DOI: 10.1055/s-2001-11153
Cutaneous manifestations in inflammatory bowel disease[]*
Publikationsverlauf
3.7.2000
31.8.2000
Publikationsdatum:
31. Dezember 2001 (online)
Summary
Numerous extraintestinal manifestations in various organ systems have been reported to be associated with inflammatory bowel disease (IBD). Aim of the present paper was to evaluate the frequency of cutaneous manifestations in Crohn’s disease (CD) and ulcerative colitis (UC) with respect to their location, the activity and location of the underlying disease, the treatment options and the time to remission.
Methods: The medical records of 1043 inpatients with CD and UC were screened retrospectively for extraintestinal symptoms with special regard to cutaneous manifestations.
Results: The prevalence of cutaneous manifestations in IBD was 22/1043 (2.1 %; 18 women, 4 men; age: 31.41 ± 9.9 [21 51] yrs.). In 15/22 patients (68.2 %) the cutaneous manifestations were associated with CD, in 7/22 patients (31.8 %) UC was confirmed. In 6/22 patients (27.3 %) pyoderma gangrenosum (PG) was diagnosed, in 16/22 patients (72.7 %) erythema nodosum (EN). EN and PG predominately occurred at the lower legs: In 68.1 % the tibia was the main affection site. Other locations like breast or anus were rare. In 16/22 patients (72.7 %) an acute phase of the underlying disease was evident, in 6/22 patients (27.3 %) CD or UC were in remission. In patients with CD a colonic involvement was found in 86.7 %. Arthritis was the most frequent coexisting extraintestinal manifestation in CD (53.3 %) and UC (28.8 %). Drug treatment was performed with high doses of glucocorticoids and salicylates. The time to remission in patients with EN was significantly shorter as compared to PG (5.3 ± 1.8 vs. 19.6 ± 14.2 weeks; p < 0.001). In 5/22 patients (22.7 %) cutaneous manifestations reoccurred after a symptom-free interval. All efflorescenses reoccurred during an active phase of the underlying disease at the same manifestation site as the initial presentation.
Conclusion: In this series the prevalence of cutaneous manifestations in IBD was 22/1043 (2.1 %). EN and PG were more frequent in women with IBD, in CD, and during the acute phases of the underlying disease. EN and PG predominately affect the lower legs. Cutaneous manifestations respond well to an acute phase therapy of the underlying disease. The time to remission was significantly shorter in EN as compared to PG. However, relapses have to be considered in a relevant subgroup of patients.
Hautveränderungen bei chronisch-entzündlichen Darmerkrankungen
Zahlreiche extraintestinale Manifestationen in unterschiedlichen Organsystemen sind bei chronisch-entzündlichen Darmerkrankungen (CED) beschrieben worden. Ziel der vorliegenden Arbeit war es, die Häufigkeit kutaner Manifestationen bei Morbus Crohn (MC) und Colitis ulcerosa (CU) unter besonderer Berücksichtigung der Lokalisation, der Aktivität und Lokalisation der Grunderkrankung, der Behandlungsregime und der Zeit bis zur Remission zu untersuchen.
Methoden: Die Krankenakten von 1043 stationären Patienten mit MC und CU wurden hinsichtlich extraintestinaler Manifestationen im Bereich der Haut retrospektiv ausgewertet.
Ergebnisse: Die Häufigkeit kutaner Manifestationen bei CED betrug 22/1043 (2,1 %; 18 Frauen, 4 Männer; Alter: 31,41 ± 9,0 [21 51] Jahre). Bei 15/22 Patienten (68,2 %) lag ein MC vor, bei 7/22 Patienten (31,8 %) eine CU. Bei 6/22 Patienten (27,3 %) wurde ein Pyoderma gangrenosum (PG) diagnostiziert, bei 16/22 Patienten (72,7 %) ein Erythema nodosum (EN). EN und PG traten bevorzugt an den unteren Extremitäten auf: Bei 68,1 % war die Tibia die Prädilektionsstelle. Andere Manifestationsorte wie Brust oder Anus waren selten. Bei 16/22 (72,7 %) der Patienten (27,3 %) waren MC oder CU in Remission. Bei Patienten mit MC wurde in 86,7 % eine Kolonbeteiligung festgestellt. Arthritiden waren mit 53,3 % (MC) bzw. 28,8 % (CU) das häufigste gleichzeitig auftretende extraintestinale Symptom. Die medikamentöse Therapie wurde mit hohen Steroiddosen und Aminosalizyten durchgeführt. Die Zeit bis zum Abheilen der Effloreszenzen war bei EN signifikant kürzer als bei PG (5,3 ± 1,8 vs. 19,6 ± 14,2 Wochen; p < 0,001). Bei 5/22 Patienten (22,7 %) kam es zu einem Rezidiv der Hautsymptome nach einem symptomfreien Intervall. Alle Rezidive traten während akuter Krankheitsphasen und an den Stellen der Primäreffloreszenz auf.
Folgerung: PG und EN sind seltene extraintestinale Symptome bei CED, die mehrheitlich während akuter Krankheitsphasen auftreten. Meist sind Frauen und Patienten mit MC betroffen. EN und PG treten bevorzugt an den unteren Extremitäten auf und sprechen recht gut auf die Akute-Phase-Therapie der Grunderkrankung an. Die Abheilungszeiten sind bei Patienten mit EN signifikant kürzer als bei PG. Rezidive müssen jedoch berücksichtigt werden.
Key words
Erythema Nodosum - Pyoderma Gangrenosum - Crohn’s Disease - Ulcerative Colitis
Schlüsselwörter
Erythema nodosum - Pyoderma gangränosum - Morbus Crohn - Colitis ulcerosa
1 Dedicated to Prof. Dr. B. May (Bochum) on occasion of his 65th birthday
References
- 1 Danzi J T. Extraintestinal manifestations of idiopathic inflammatory bowel disease. Arch Intern Med. 1988; 148 297-302
- 2 Greenstein A J, Janowitz H D, Sachar D. The extraintestinal complications of Crohn’s disease and ulcerative colitis: A study of 700 patients. Medicine. 1976; 55 401-412
- 3 Monsen U, Sorstad J, Hellers G, Johansson C. Extracolonic diagnoses in ulcerative colitis: An epidemiological study. Am J Gastroenterol. 1985; 85 711-716
- 4 Rankin G B, Watts H D, Melnyk C S, Kelley M L. National Cooperative Crohn’s Disease Study: Extraintestinal manifestations and perianal complications. Gastroenterology. 1979; 77 914-920
- 5 Veloso F T, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996; 23 29-34
- 6 Apgar J T. Never aspects of inflammatory bowel disease and its cutaneous manifestations: A selective review. Sem Dermatol. 1991; 10 138-147
- 7 Farmer R G, Hawk W A, Turnbull R B. Clinical patterns in Crohn’s disease: A statistical study of 615 cases. Gastroenterology. 1975; 68 627-635
- 8 Goebell H, Förster S, Dirks E. et al . Morbus Crohn: Klinische Erkrankungsmuster in Beziehung zur Lokalisation. Med Klin. 1987; 82 1-8
- 9 Linaker B D. Erythema nodosum presenting before inflammatory bowel disease. Lancet. 1977; 29 931
- 10 Adler G. Morbus Crohn - Colitis ulcerosa. Heidelberg; Springer-Verlag 1996
- 11 May B. Extraintestinale Manifestationen der chronisch entzündlichen Darmerkrankungen. Leber Magen Darm. 1997; 29 17-20 (3)
- 12 Areias E, Garcia e Silva L. Cutaneous manifestations of ulcerative colitis (Portogese). Med Cutan Ibero Lat Am. 1987; 15 185-187
- 13 Kirsch B, Gerhardt H, Gladisch R. et al . Dermatosen bei chronisch entzündlichen Darmerkrankungen. Ergebnisse einer Untersuchung von 119 M.-Crohn-/C.-ulcerosa-Patienten. Akt Dermatol. 1992; 18 17-22
- 14 Yates V M, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn’s disease and ulcerative colitis. Br J Dermatol. 1982; 106 323-330
- 15 Sigl I, Bauerdorf R. Granulomatous rosacea associated with ulcerative colitis: 2 case reports (German). Z Hautkr. 1989; 64 499-502
- 16 Shum D T, Guenther L. Metastatic Crohn’s disease. Arch Dermatol. 1990; 126 645-648
- 17 Lamers C BHW. Treatment of extraintestinal complications of ulcerative colitis. Eur J Gastroenterol Hepatol. 1997; 9 850-853
- 18 Gregory B, Ho V C. Continuing medical education: Cutaneous manifestations of gastrointestinal disorders. Part II. J Am Acad Dermatol. 1992; 26 371-383
- 19 Marshall J K, Irvine E J. Successful therapy of refractory erythema nodosum associated with Crohn’s disease using potassium sodide. Can J Gastroenterol. 1997; 11 501-502
- 20 Levine J B, Lukawski-Trubish D. Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Am. 1995; 24 633-646
- 21 Phillips W G, Marsden J R. Skin disease in gastroenterology. Gastroenterology: Clinical science and practice 2 Philadelphia; WB Saunders Company 1993: 1328-1340
- 22 Basler R SW. Ulcerative colitis and the skin. Gut. 1980; 64 941-944
- 23 Ochsendorf F R. Cutaneous manifestations of IBD and IBD-associated inflammatory lesions. Lembcke B, Kruis W, Sartor RB Kluver Academic Publishers Systemic manifestations of IBD - The pending challenge for subile diagnosis and treatment Frankfurt, Köln, Chapel Hill; 1998: 67-93
- 24 McCord M L, Hall R P. Cutaneous manifestations of inflammatory bowel disease. Targan Sr, Shanahan F Inflammatory Bowel Disease: From bench to bedside Baltimore, Philadelphia, Hong Kong, London, Munich, Sydney, Tokyo; Williams & Wilkins 1994: 682-694
- 25 Bargen J A. Complications and sequelae of chronic ulcerative colitis. Ann Intern Med. 1929; 3 335-352
- 26 Brunsting L A, Goeckermann W H, O’Leary PA. Pyoderma (ecthyma) gangrenosum. Clinical and experimental observations in 5 cases occurring in adults. Arch Dermatol. 1930; 22 655-680
- 27 Schoetz D J, Coller J A, Veidenheimer M C. Pyoderma gangrenosum and Crohn’s disease. Eight cases and a review of the literature. Dis Colon Rectum. 1983; 26 155-158
- 28 Levitt M D, Ritchie J K, Lennard-Jones J E, Phillips R K. Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg. 1991; 78 676-678
- 29 Hüppe D, Schenck B, Tromm A. Extraintestinale Manifestation und Komplikationen bei chronisch aktivem Verlauf der Colitis ulcerosa im Kindes- und Jugendalter. Dtsch Med Wochenschr. 1999; 124 824-828
- 30 Lysy J, Zimmerman J, Ackerman Z, Reifen E. Atypical auricular pyoderma gangrenosum simulating fungal infection. J Clin Gastroenterol. 1989; 11 561-564
- 31 Cerdan F J, Cantero R, Martinez S. et al . Die gangränöse Pyodermie am Kolostoma eines Patienten mit Morbus Crohn. Coloproctology. 1994; 16 407-410
- 32 Cairns B A, Herbst C A, Sartor B R, Brigamann R A, Koruda M J. Peristomal pyoderma gangrenosum and inflammatory bowel disease. Arch Surg. 1994; 129 769-772
- 33 Giroux J M, Quellet A, Heppell J, Lacroix M. Peristomal pyoderma gangrenosum in a patient with ulcero-hemorrhagic rectocolitis. Ann Dermatol Venerol. 1987; 114 935-939
- 34 Holmlund D E, Wahlby L. Pyoderma gangrenosum after colectomy for inflammatory bowel disease. Case report. Acta Chir Scand. 1987; 153 73-74
- 35 Keltz M, Lebwohl M, Bishop S. Peristomal pyoderma gangrenosum. J Am Acad Dermatol. 1992; 27 360-364
- 36 Ng C S, Wolfsen H C, Kozarek R A, Brubacher L L, Kayne A L. Chronic parastomal ulcers: Spectrum of dermatoses. J Et Nurs. 1992; 19 85-90
- 37 Tjandra J J, Hughes L E. Parastomal pyoderma gangrenosum in inflammatory bowel disease. Dis Colon Rectum. 1994; 37 938-942
- 38 Graham J A, Hansen K K, Rabinowitz L G, Esterly N B. Pyoderma gangrenosum in infants and children. Pediatr Dermatol. 1994; 11 10-17
- 39 Snyder R A. Pyoderma gangrenosum involving the head and neck. Arch Dermatol. 1986; 12 295-302
- 40 Lilford R J, Tindall V R, Batchelor A G. Post-surgical pyoderma gangrenosum of the vaginal fault associated with ulcerative colitis and behcet’s disease: A case report. Eur J Obstet Gynecol Reprod Biol. 1989; 31 93-94
- 41 Sanusi I D, Gonzales E, Venable D D. Pyoderma granulomatosa of penile and scrotal skin. J Urol. 1982; 117 547-549
- 42 Klein J D, Biller J A, Leape L I, Grand R J. Pyoderma gangrenosum occurring at multiple surgical incision sites. Gastroenterology. 1987; 92 810-813
- 43 Powell F C, Schroeter A L, Su W P, Perry H O. Pyoderma gangrenosum: A review of 86 patients. Q J Med. 1995; 55 173-186
- 44 Cox N H, Peebes-Brown D A, MacKie R M. Pyoderma gangrenosum occurring 10 years after proctocolectomy for ulcerative colitis. Br J Hosp Med. 1986; 36 363
- 45 Talansky A L, Meyers S, Greenstein A J, Janowitz H D. Does intestinal resection heal the pyoderma gangrenosum of inflammatory bowel disease?. J Clin Gastroenterol. 1980; 5 207-210
- 46 Novell L M, Malkinson F D. Commentary: Pyoderma gangrenosum. Arch Dermatol. 1982; 118 769-773
- 47 Warneke B, Breitbart E W, Nasemann T. Pyoderma gangrenosum with special reference to immunologic and hematologic parameters. Z Hautkr. 1988; 63 398-408
- 48 Das K M, Squillante L, Chitayet D, Kalloussek D K. Simultaneous appearance of a unique common epitope in fetal colon, skin, and biliary epithelial cells. A possible link for extra-colonic manifestations in ulcerative colitis. J Clin Gastroenterol. 1992; 15 311-316
- 49 Hüner A, Hornstein O P, von den Driesch P. Pyoderma gangraenosum: Klinik, assoziierte Erkrankungen und Therapiemöglichkeiten. Dtsch Ärztebl. 1995; 92 B1467-1471
- 50 Hoogkamp-Korstanje J A, de Koning J. Clinical aspects, diagnosis and therapy of Yersinia enterocolitica infections. Immun Infekt. 1990; 18 192-197
- 51 Stolk-Engelaer V M, Hoogkamp-Kortanje J A. Clinical presentation and diagnosis of gastrointestinal infections by Yersinia enterocolitica in 261 Dutch patients. Scand J Infect Dis. 1996; 28 571-575
- 52 Klein S, Mayer L, Present D H. et al . Extraintestinal manifestations in patients with diverticulitis. Ann Intern Med. 1988; 108 700-702
- 53 Chow R KP, Ho V C. Treatment of pyoderma gangrenosum. J Am Acad Dermatol. 1996; 34 1047-1060
- 54 Schwaegerle S M, Bergfeld W F, Wenitzer D, Tidrick R T. Pyoderma gangrenosum: A review. J Am Acad Dermatol. 1988; 18 559-568
- 55 Stone O J. Sulfapyridine and sulfones decrease glycosaminoglycans viscosity in dermatitis herpetiformis, ulcerative colitis, and pyoderma gangrenosum. Med Hypotheses. 1990; 31 99-103
- 56 Prochazka V, Rozkovcova J. Successful treatment with the Imuran and prednisone combination. Cesk Dermatol. 1985; 56 173-177
- 57 Elgart G, Storek P, Larson K. et al . Treatment of pyoderma gangrenosum with cyclosporine: Results in seven patients. J Am Acad Dermatol. 1991; 24 83-86
- 58 Matis W L, Ellis C N, Griffiths C E, Lazarus G S. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol. 1992; 128 1060-1064
- 59 Shelley E D, Shelley W B. Cyclosporine therapy of pyoderma gangrenosum associated with sclerosing cholangitis and ulcerative colitis. J Am Acad Dermatol. 1988; 18 1084-1088
- 60 Kaplan B, Trau H, Soefer E, Feinstein A, Schwebach-Millet M. Treatment of Pyoderma gangrenosum with clofacimine. Int J Dermatol. 1992; 31 591-593
- 61 Callen J P, Case J D, Sager D. Chlorambucil is effective in pyoderma gangrenosum. J Am Acad Dermatol. 1989; 21 515-519
- 62 Galun E, Flugelman M Y, Rachmilewitz D. Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and Dapsone. Am J Gastroenterol. 1986; 81 988-989
- 63 Schorr-Lesnick B, Brandt L J. Selected rheumatological and dermatological manifestations of inflammatory bowel disease. Am J Gastroenterol. 1988; 83 216-223
- 64 Cave D R, Burakoff R. Pyoderma gangrenosum associated with ulcerative colitis: Treatment with disodium cromoglycate. Am J Gastroenterol. 1987; 82 802-804
- 65 Saffouri B, Horn B M, Metersdorf J M, Gardiner J E. Treatment of pyoderma gangrenosum with disodium cromoglycate. Dig Dis Sci. 1984; 29 183-185
- 66 Richardson J B, Callen J P. Pyoderma gangrenosum treated successfully with potassium iodide. J Am Acad Dermatol. 1993; 28 1005-1007
- 67 Goldstein F, Krain R, Thorton J J. Intralesional steroid therapy of pyoderma gangrenosum. J Clin Gastroenterol. 1991; 7 499-501
- 68 Mir-Madjlessi S H, Taylor J S, Farmer R G. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: A study of 42 patients. Am J Gastroenterol. 1985; 80 615-620
- 69 Bennent M L, Jackson J M, Jorizzo J L. et al . Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine. 2000; 79 37-46
1 Dedicated to Prof. Dr. B. May (Bochum) on occasion of his 65th birthday
Address for correspondence
Priv.-Doz. Dr. med. Andreas Tromm
Klinik für Innere Medizin Evangelisches Krankenhaus Hattingen
Akademisches Lehrkrankenhaus der RUB
Bredenscheider Straße 54
45525 Hattingen
eMail: Andreas.Tromm@ruhr-uni-bochum.de